Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 3607-3619

  Hegarty, John P ^a   Krzeminski, Jacek ^b   Sharma, Arun K ^b   Guzman Villanueva, Diana ^c   Weissig, Volkmar ^c   Stewart, David B ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Antisense; Bacteria; Cationic bolaamphiphiles; Clostridium difficile; Dequalinium derivatives; Gapmers; Nanocomplex

Indexed keywords

AMPHOPHILE; ANTISENSE OLIGONUCLEOTIDE; BOLASOME; FTSZ PROTEIN; MESSENGER RNA; NANOPARTICLE; RNA POLYMERASE BETA SUBUNIT; SECY PROTEIN; UNCLASSIFIED DRUG; 5' UNTRANSLATED REGION; BOLAAMPHIPHILE; CATION; DEQUALINIUM; FURAN DERIVATIVE; LUCIFERASE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PYRIDONE DERIVATIVE;

ARTICLE; BACTERIAL GROWTH; BINDING AFFINITY; CONTROLLED STUDY; DNAE GENE; FABD GENE; FTSZ GENE; GENE; GENE EXPRESSION; GENE TARGETING; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARTICLE SIZE; PEPTOCLOSTRIDIUM DIFFICILE; PLASMID; PRLA GENE; RNA TRANSLATION; RPOB GENE; SECY GENE; ZETA POTENTIAL; 5' UNTRANSLATED REGION; CHEMISTRY; CONFORMATION; DENSITOMETRY; DRUG EFFECTS; GENETICS; IMMUNOBLOTTING; METABOLISM; PROTEIN SYNTHESIS; REPORTER GENE; STATIC ELECTRICITY;

5' UNTRANSLATED REGIONS; CATIONS; CLOSTRIDIUM DIFFICILE; DENSITOMETRY; DEQUALINIUM; FURANS; GENES, REPORTER; IMMUNOBLOTTING; LUCIFERASES; NANOPARTICLES; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PLASMIDS; PROTEIN BIOSYNTHESIS; PYRIDONES; STATIC ELECTRICITY;

EID: 84982693531     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S109600     Document Type: Article

References (55)

1. Davies AH, Roberts AK, Shone CC, Acharya KR. Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem J. 2011;436(3):517–526.
2. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769–1775.
3. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693–702.
4. Steglich M, Nitsche A, Von Müller L, et al. Tracing the spread of Clostridium difficile ribotype 027 in Germany based on bacterial genome sequences. PLoS One. 2015;10(10):e0139811.
5. Gilliland C, Weaver J, Stevenson M, et al. Association of Clostridium difficile ribotype 078 with detectable toxin in human stool specimens. J Med Microbiol. 2015;64(11):1341–1345.
6. Carlson PE, Walk ST, Bourgis AE, et al. The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates. Anaerobe. 2013;24:109–116.
7. Archbald-Pannone LR, Boone JH, Carman RJ, Lyerly DM, Guerrant RL. Clostridium difficile ribotype 027 is most prevalent among inpatients admitted from long-term care facilities. J Hosp Infect. 2014;88(4):218–221.
8. Bai H, Xue X, Hou Z, Zhou Y, Meng J, Luo X. Antisense antibiotics: a brief review of novel target discovery and delivery. Curr Drug Discov Technol. 2010;7(2):76–85.
9. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol. 2007;3(9):541–548.
10. Rasmussen LC, Sperling-Petersen HU, Mortensen KK. Hitting bacteria at the heart of the central dogma: sequence-specific inhibition. Microb Cell Fact. 2007;6(1):24.
11. Dinan AM, Loftus BJ. (Non-)translational medicine: targeting bacterial RNA. Front Genet. 2013;4(Nov):230.
12. Ji Y, Lei T. Antisense RNA regulation and application in the development of novel antibiotics to combat multidrug resistant bacteria. Sci Prog. 2013;96(1):43–60.
13. Järver P, Coursindel T, Andaloussi SE, Godfrey C, Wood MJ, Gait MJ. Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol Ther Nucleic Acids. 2012;1(6):e27.
14. Hansen AM, Bonke G, Larsen CJ, Yavari N, Nielsen PE, Franzyk H. Antibacterial peptide nucleic acid – antimicrobial peptide (PNA-AMP) conjugates: antisense targeting of fatty acid biosynthesis. Bioconjug Chem. 2016;27(4):863–867.
15. Geller BL, Marshall-Batty K, Schnell FJ, McKnight MM, Iversen PL, Greenberg DE. Gene-silencing antisense oligomers inhibit Acinetobacter growth in vitro and in vivo. J Infect Dis. 2013;208(10):1553–1560.
16. Wang H, Meng J, Jia M, et al. oprM as a new target for reversion of multidrug resistance in Pseudomonas aeruginosa by antisense phosphorothioate oligodeoxynucleotides. FEMS Immunol Med Microbiol. 2010;60(3):275–282.
17. Meng J, Da F, Ma X, et al. Antisense growth inhibition of methicillin-resistant Staphylococcus aureus by locked nucleic acid conjugated with cell-penetrating peptide as a novel FtsZ inhibitor. Antimicrob Agents Chemother. 2015;59(2):914–922.
18. Patenge N, Pappesch R, Krawack F, et al. Inhibition of growth and gene expression by PNA-peptide conjugates in streptococcus pyogenes. Mol Ther Nucleic Acids. 2013;2(April):e132.
19. Hegarty JP, Sangster W, Harris LR, Durdach M, Stewart DB. Targeted silencing of essential C. difficile genes using antisense morpholino-peptide conjugates. Presented at: 2015 American Society for Microbiology. 115th General Meeting; 2015; New Orleans, LA; 011:51.
20. Zhao XB, Pan F, Zhang ZQ, et al. Nanostructure of polyplexes formed between cationic diblock copolymer and antisense oligodeoxynucleotide and its influence on cell transfection efficiency. Biomacromolecules. 2007;8(11):3493–3502.
21. Chen Z, Hu Y, Meng J, et al. Efficient transfection of phosphorothioate oligodeoxyribonucleotides by lipofectamine 2000 into different bacteria. Curr Drug Deliv. 2015;12:1–8.
22. Zhang L, Pornpattananangku D, Hu C-MJ, Huang C-M. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010;17(6):585–594.
23. Khameneh B, Diab R, Ghazvini K, Fazly Bazzaz BS. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb Pathog. 2016;95:32–42.
24. Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans K. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J Control Release. 2014;190:607–623.
25. Hong CA, Nam YS. Functional nanostructures for effective delivery of small interfering RNA therapeutics. Theranostics. 2014;4(12):1211–1232.
26. Khan M, Ang CY, Wiradharma N, et al. Diaminododecane-based cationic bolaamphiphile as a non-viral gene delivery carrier. Biomaterials. 2012;33(18):4673–4680.
27. Lyrawati D, Trounson A, Cram D. Expression of GFP in the mitochondrial compartment using DQAsome-mediated delivery of an artificial mini-mitochondrial genome. Pharm Res. 2011;28(11):2848–2862.
28. Weissig V, Lasch J, Erdos G, Meyer H, Rowe T, Hughes J. DQAsomes: a novel potential drug and gene delivery system made from dequalinium. Pharm Res. 1998;15(2):334–337.
29. Weissig V, Lizano C, Torchilin VP. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv. 2000;7(1):1–5.
30. Weissig V, Lizano C, Ganellin C, Torchilin V. DNA binding cationic bolasomes with delocalized charge center – a structure-activity relationship study. STP Pharma Sci. 2001;11(1):91–96.
31. Weissig V. From serendipity to mitochondria-targeted nanocarriers. Pharm Res. 2011;28(11):2657–2668.
32. Grinberg S, Stern A, Guidotti M, et al. Steric environment around acetylcholine head groups of bolaamphiphilic nanovesicles influences the release rate of encapsulated compounds. Int J Nanomedicine. 2014;9:561.
33. Schlame M. Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. J Lipid Res. 2008;49(8):1607–1620.
34. Guan Z, Katzianer D, Zhu J, Goldfine H. Clostridium difficile contains plasmalogen species of phospholipids and glycolipids. Biochim Biophys Acta. 2014;1841(10):1353–1359.
35. Yoo BH, Bochkareva E, Bochkarev A, Mou T-C, Gray DM. 2′-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Res. 2004;32(6):2008–2016.
36. Niemietz C, Chandhok G, Schmidt H. Therapeutic oligonucleotides targeting liver disease: TTR amyloidosis. Molecules. 2015;20(10):17944–17975.
37. Chan JH, Lim S, Wong WF. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol. 2006;33(5–6):533–540.
38. Stewart DB, Berg AS, Hegarty JP. Single nucleotide polymorphisms of the tcdC gene and presence of the binary toxin gene predict recurrent episodes of Clostridium difficile infection. Ann Surg. 2014;260(2):299–304.
39. Stubbs SL, Brazier JS, O’Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol. 1999;37(2):461–463.
40. Rupnik M, Avesani V, Janc M, Von Eichel-Streiber C, Delmée M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol. 1998;36(8):2240–2247.
41. Adey A, Morrison HG, Asan, et al. Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density in vitro transposition. Genome Biol. 2010;11(12):R119.
42. Dembek M, Barquist L, Boinett CJ, et al. High-throughput analysis of gene essentiality and sporulation in Clostridium difficile. MBio. 2015;6(2):e02383.
43. Lima WF, Vickers TA, Nichols J, Li C, Crooke ST. Defining the factors that contribute to on-target specificity of antisense oligonucleotides. PLoS One. 2014;9(7):e101752.
44. Reuter JS, Mathews DH. RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics. 2010;11(1):129.
45. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31(13):3406–3415.
46. Gish W, Altschul SF, Lipman DJ, Miller W, Myers EW. Basic local alignment search tool. J Mol Biol. 1990;215(3):403–410.
47. Shao Y, Wu Y, Chan CY, McDonough K, Ding Y. Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation. Nucleic Acids Res. 2006;34(19):5660–5669.
48. Zaher HS, Green R. In vitro synthesis of proteins in bacterial extracts. Methods Enzymol. 2014;539:3–15.
49. Weissig V. DQAsomes as the prototype of mitochondria-targeted pharmaceutical nanocarriers: preparation, characterization, and use. Methods Mol Biol. 2015;1265:1–11.
50. Márquez-Miranda V, Peñaloza JP, Araya-Durán I, et al. Effect of terminal groups of dendrimers in the complexation with antisense oligonucleotides and cell uptake. Nanoscale Res Lett. 2016;11(1):66.
51. European Society of Clinical Microbiology and Infectious Diseases. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin Microbiol Infect. 2003;9(8):1–7.
52. Jerchel D, Ost W, Klaus T. Quaternary derivatives of 1,2,3,4-tetra-hydro-9-amino-acridine. US patent 3519631; 1970.
53. Weissig V, Torchilin VP. Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy. Curr Pharm Biotechnol. 2000;1(4):325–346.
54. Zhao Q-Q, Chen J-L, Lv T-F, et al. N/P ratio significantly influences the transfection efficiency and cytotoxicity of a polyethylenimine/chitosan/DNA complex. Biol Pharm Bull. 2009;32(4):706–710.
55. Bai H, Zhou Y, Hou Z, Xue X, Meng J, Luo X. Targeting bacterial RNA polymerase: promises for future antisense antibiotics development. Infect Disord Drug Targets. 2011;11(2):175–187.